Empowered Patient Podcast

Adam Sachs is the Co-Founder and CEO of Vicarious Surgical a next generation robotics company that is developing a disruptive medical technology platform. Their goal is to increase the efficiency of legacy surgical robotics, improving patient outcomes and reducing healthcare costs. Vicarious Surgical's novel approach to surgery uses a combination of proprietary miniaturized surgical robots and virtual reality to transport surgeons inside the patient when performing minimally invasive surgery.

The first indication being targeted is ventral hernia repair for which Vicarious has been granted Breakthrough Device Special designation from the FDA. The Vicarious system, with nine-degrees of freedom for each arm of the robot, can actually operate from inside of the abdomen out. Surgeons are enthusiastic about the ability to work facing any direction from any incision site.

#VicariousSurgery #VR #VirtualReality #robots #surgicalrobotics #herniarepair #ventralherniarepair #SPAC

VicariousSurgery.com

Listen to the podcast here

Adam Sachs is the Co-Founder and CEO of Vicarious Surgical a next generation robotics company that is developing a disruptive medical technology platform. Their goal is to increase the efficiency of legacy surgical robotics, improving patient outcomes and reducing healthcare costs. Vicarious Surgical's novel approach to surgery uses a combination of proprietary miniaturized surgical robots and virtual reality to transport surgeons inside the patient when performing minimally invasive surgery.

The first indication being targeted is ventral hernia repair for which Vicarious has been granted Breakthrough Device Special designation from the FDA. The Vicarious system, with nine-degrees of freedom for each arm of the robot, can actually operate from inside of the abdomen out. Surgeons are enthusiastic about the ability to work facing any direction from any incision site.

#VicariousSurgery #VR #VirtualReality #robots #surgicalrobotics #herniarepair #ventralherniarepair #SPAC

VicariousSurgery.com

Download the transcript here

Dr. Kishlay Anand is a practicing cardiologist and Founder and President of Apricus Health, a healthcare provider with a focus on having a dedicated care navigator work with patients to help them on their healthcare journey. This includes coordinating appointments with primary care physicians, specialists, remote monitoring, medication refills, updates on community resources and education about chronic conditions. Not only does this benefit patients but also doctors as it reduces paperwork and allows them to focus on transitioning from fee-for-service to value-based care.

Apricus is developing digital health technology tailored to the unique challenges seniors and those with chronic conditions face. Of particular interest is the senior patient population which due to COVID-19 has had a chance to experience virtual doctor visits and telehealth interactions which have proven to be very popular.

@Apricus_Health #digitalhealth #telemedicine #telehealth #personalizedmedicine #MedTech

ApricusHealth.com

Listen to the podcast here

Dr. Kishlay Anand is a practicing cardiologist and Founder and President of Apricus Health, a healthcare provider with a focus on having a dedicated care navigator work with patients to help them on their healthcare journey. This includes coordinating appointments with primary care physicians, specialists, remote monitoring, medication refills, updates on community resources and education about chronic conditions. Not only does this benefit patients but also doctors as it reduces paperwork and allows them to focus on transitioning from fee-for-service to value-based care.

Apricus is developing digital health technology tailored to the unique challenges seniors and those with chronic conditions face. Of particular interest is the senior patient population which due to COVID-19 has had a chance to experience virtual doctor visits and telehealth interactions which have proven to be very popular.

@Apricus_Health #digitalhealth #telemedicine #telehealth #personalizedmedicine #MedTech

ApricusHealth.com

Download the transcript here

John Schwartz is Chief Revenue Officer at HSBlox and he strongly believes that care coordination is essential for all patients. The challenge is how can healthcare stakeholders improve the delivery of Social Determinants of Health (SDOH) to better serve vulnerable people. Aligning medical and social care needs is a messy issue and there needs to be a stronger recognition of how much the environment determines health of a population.

HSBlox enables SDOH risk-stratification, care coordination and appropriate data sharing through its digital health platform. It applies AI, machine learning and blockchain technologies to streamline SDOH processes of data exchange, patient consent management and referral optimization.

@blox_hs #HSBlox #VBC #AI #valuebasedcare #healthcareAI #healthcaredata #patientadherence #SDOH #socialdeterminantsofhealth #populationhealth #precisionhealth #DistributedLedgerTechnology

HSBlox.com

Listen to the podcast here

John Schwartz is Chief Revenue Officer at HSBlox and he strongly believes that care coordination is essential for all patients. The challenge is how can healthcare stakeholders improve the delivery of Social Determinants of Health (SDOH) to better serve vulnerable people. Aligning medical and social care needs is a messy issue and there needs to be a stronger recognition of how much the environment determines health of a population.

HSBlox enables SDOH risk-stratification, care coordination and appropriate data sharing through its digital health platform. It applies AI, machine learning and blockchain technologies to streamline SDOH processes of data exchange, patient consent management and referral optimization.

@blox_hs #HSBlox #VBC #AI #valuebasedcare #healthcareAI #healthcaredata #patientadherence #SDOH #socialdeterminantsofhealth #populationhealth #precisionhealth #DistributedLedgerTechnology

HSBlox.com

Download the transcript here

Dr. Ian Walters is CEO of Portage Biotech is building a pipeline of novel immunotherapies for the treatment of cancer particularly for patients who do not respond to current therapies. The key is stimulating a type of immune cell called invariant natural killer T-cell which works with the adaptive immune system to create a broad immune response and stronger immune surveillance to help stop cancer from forming in the body.

Having contributed to bringing five new blockbuster cancer drugs to patients, Ian and his team are working to hit all key components for every different tumor type for a long-term response and possible cure. They think their drug could have potential in settings that wouldn't respond to just pure NK cell therapy.

#ImmunoOncology #Cancer #iNKT #biotech $PRTG

PortageBiotech.com

Listen to the podcast here

Dr. Ian Walters is CEO of Portage Biotech is building a pipeline of novel immunotherapies for the treatment of cancer particularly for patients who do not respond to current therapies. The key is stimulating a type of immune cell called invariant natural killer T-cell which works with the adaptive immune system to create a broad immune response and stronger immune surveillance to help stop cancer from forming in the body.

Having contributed to bringing five new blockbuster cancer drugs to patients, Ian and his team are working to hit all key components for every different tumor type for a long-term response and possible cure. They think their drug could have potential in settings that wouldn't respond to just pure NK cell therapy.

#ImmunoOncology #Cancer #iNKT #biotech $PRTG

PortageBiotech.com

Download the transcript here

Manolo Bellotto, PhD is General Manager and President Gain Therapeutics and dedicated to redefining drug discovery through the use of supercomputers and proprietary algorithms to understand rare diseases and diseases where there is a high medical need related to protein misfolding. These indications include cancer, neurodegenerative, metabolic and inflammatory diseases.

While traditional drug discovery around protein misfolding was through high-throughput screening, Gain can efficiently identify a select group of molecules that can potentially correct misfolding or induce misfolding of specific proteins. In a short period of time, using a personalized approach in each different target, they have the biological characterization to see if they can intervene on the protein, potentially leading to a pharmacological solution.

@GainThera #ProteinMisfolding #DrugDiscovery #RareDisease #Oncology #LysosomalStorageDisorders #Neurodegenerative #Supercomputer #technology #ComputationalChemistry

GainTherapeutics.com

Listen to the podcast here

Manolo Bellotto, PhD is General Manager and President Gain Therapeutics and dedicated to redefining drug discovery through the use of supercomputers and proprietary algorithms to understand rare diseases and diseases where there is a high medical need related to protein misfolding. These indications include cancer, neurodegenerative, metabolic and inflammatory diseases.

While traditional drug discovery around protein misfolding was through high-throughput screening, Gain can efficiently identify a select group of molecules that can potentially correct misfolding or induce misfolding of specific proteins. In a short period of time, using a personalized approach in each different target, they have the biological characterization to see if they can intervene on the protein, potentially leading to a pharmacological solution.

@GainThera #ProteinMisfolding #DrugDiscovery #RareDisease #Oncology #LysosomalStorageDisorders #Neurodegenerative #Supercomputer #technology #ComputationalChemistry

GainTherapeutics.com

Download the transcript here